Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IGMS NASDAQ:JAN NASDAQ:JMAC NASDAQ:MIST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGMSIGM Biosciences$1.27$1.27$0.92▼$22.50$76.57M0.6480,746 shsN/AJANJanOne$2.57$0.22▼$5.26$20.03M2.16229,417 shs139,500 shsJMACMaxpro Capital Acquisition$5.80+0.3%$6.13$7.50▼$19.22$77.88M0.0174,040 shs43,353 shsMISTMilestone Pharmaceuticals$1.70+1.2%$1.71$0.63▼$2.75$89.82M0.521.01 million shs866,536 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGMSIGM Biosciences-0.78%0.00%0.00%+7.63%-85.44%JANJanOne0.00%0.00%0.00%0.00%0.00%JMACMaxpro Capital Acquisition0.00%+4.13%+1.05%+18.61%+4,028.11%MISTMilestone Pharmaceuticals+1.19%+13.33%+1.80%+39.34%+19.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGMSIGM Biosciences4.5962 of 5 stars3.03.00.04.63.83.31.3JANJanOneN/AN/AN/AN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMISTMilestone Pharmaceuticals1.6247 of 5 stars3.21.00.00.01.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGMSIGM Biosciences 1.90Reduce$5.50333.07% UpsideJANJanOne 0.00N/AN/AN/AJMACMaxpro Capital Acquisition 0.00N/AN/AN/AMISTMilestone Pharmaceuticals 2.40Hold$7.00311.76% UpsideCurrent Analyst Ratings BreakdownLatest JAN, MIST, JMAC, and IGMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$5.00(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGMSIGM Biosciences$2.68M28.57N/AN/A$1.67 per share0.76JANJanOne$39.61M0.00N/AN/A($0.67) per share0.00JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AMISTMilestone Pharmaceuticals$1M90.88N/AN/A($0.33) per share-5.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGMSIGM Biosciences-$195.79M-$0.90N/AN/AN/A-36.81%-93.35%-24.15%N/AJANJanOne-$7.81MN/A0.00N/AN/AN/A-359.71%-70.26%N/AJMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AMISTMilestone Pharmaceuticals-$41.52M-$0.84N/AN/AN/AN/A-1,672.29%-83.09%N/ALatest JAN, MIST, JMAC, and IGMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MISTMilestone Pharmaceuticals-$0.18-$0.20-$0.02-$0.20N/AN/A7/31/2025Q2 2025IGMSIGM Biosciences-$0.30$1.58+$1.88$1.58$3.20 million$143.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGMSIGM BiosciencesN/AN/AN/AN/AN/AJANJanOneN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGMSIGM BiosciencesN/A17.6617.66JANJanOneN/A0.150.15JMACMaxpro Capital AcquisitionN/AN/AN/AMISTMilestone Pharmaceuticals4.064.974.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGMSIGM Biosciences42.79%JANJanOne6.27%JMACMaxpro Capital Acquisition73.18%MISTMilestone Pharmaceuticals86.18%Insider OwnershipCompanyInsider OwnershipIGMSIGM Biosciences57.00%JANJanOne3.00%JMACMaxpro Capital Acquisition19.27%MISTMilestone Pharmaceuticals19.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIGMSIGM Biosciences19060.29 million25.93 millionOptionableJANJanOne1708.98 million8.71 millionNot OptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableMISTMilestone Pharmaceuticals3053.46 million43.04 millionOptionableJAN, MIST, JMAC, and IGMS HeadlinesRecent News About These CompaniesMilestone Pharmaceuticals (NASDAQ:MIST) Posts Earnings Results, Misses Expectations By $0.02 EPSAugust 14 at 4:18 PM | marketbeat.comMilestone Pharmaceuticals Advances CARDAMYST with FDA and Financial BoostAugust 13 at 8:28 PM | theglobeandmail.comMilestone Pharmaceuticals reports Q2 EPS (20c), consensus (18c)August 12, 2025 | msn.comMilestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateAugust 12, 2025 | globenewswire.comMilestone Pharmaceuticals (MIST) Expected to Announce Quarterly Earnings on ThursdayAugust 12, 2025 | americanbankingnews.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Sold by Alta Fundamental Advisers LLCAugust 11, 2025 | marketbeat.comAnalysts Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Price Target at $7.00August 8, 2025 | americanbankingnews.comMilestone Pharmaceuticals (MIST) to Release Earnings on ThursdayAugust 7, 2025 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from BrokeragesAugust 5, 2025 | marketbeat.comShort Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expands By 159.9%August 4, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Kestra Medical Technologies Ltd. (KMTS) and Milestone Pharmaceuticals (MIST)July 18, 2025 | theglobeandmail.comMilestone Pharmaceuticals Remains A Buying Opportunity Despite Recent DilutionJuly 18, 2025 | seekingalpha.comEquities Analysts Set Expectations for MIST Q3 EarningsJuly 17, 2025 | marketbeat.comMilestone Pharmaceuticals Announces Public Offering for $48.7MJuly 16, 2025 | theglobeandmail.comTD Cowen Sticks to Its Hold Rating for Milestone Pharmaceuticals (MIST)July 16, 2025 | theglobeandmail.comHC Wainwright Issues Pessimistic Estimate for MIST EarningsJuly 16, 2025 | marketbeat.comUS FDA accepts for review Milestone Pharma’s response to CRL for Cardamyst nasal sprayJuly 14, 2025 | pharmabiz.comPMilestone Pharmaceuticals Inc. (MIST) Stock Price Today - WSJJuly 11, 2025 | wsj.comMilestone says heart disorder therapy under FDA review againJuly 11, 2025 | msn.comMilestone Pharmaceuticals stock plunges on public offering announcementJuly 11, 2025 | au.investing.comMilestone Pharmaceuticals Shares Drop Sharply After Public Offering AnnouncementJuly 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025CrowdStrike Stock Eyes Next Move With AI in FocusBy Chris Markoch | July 29, 2025Zebra Technologies: Riding the Automation Wave to ProfitsBy Thomas Hughes | August 5, 2025JAN, MIST, JMAC, and IGMS Company DescriptionsIGM Biosciences NASDAQ:IGMS$1.27 0.00 (0.00%) As of 08/14/2025IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.JanOne NASDAQ:JANJanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.Maxpro Capital Acquisition NASDAQ:JMAC$5.80 +0.02 (+0.35%) As of 08/13/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.Milestone Pharmaceuticals NASDAQ:MIST$1.70 +0.02 (+1.19%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.68 -0.01 (-0.88%) As of 08/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Arista Networks: Cashing In as the Tollbooth for AI Traffic Green Dot's 30% Rally: Turnaround Takes Off on Explosive Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.